APA

Strangfeld A., Richter A., Siegmund B., Herzer P., Rockwitz K., Demary W., Aringer M., Meißner Y., Zink A. & Listing J. (20170613). Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. : Annals of the rheumatic diseases.

Chicago

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A and Listing J. 20170613. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. : Annals of the rheumatic diseases.

Harvard

Strangfeld A., Richter A., Siegmund B., Herzer P., Rockwitz K., Demary W., Aringer M., Meißner Y., Zink A. and Listing J. (20170613). Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. : Annals of the rheumatic diseases.

MLA

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A and Listing J. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. : Annals of the rheumatic diseases. 20170613.